City Therapeutics, Inc. (NASDAQ:CTY – Get Free Report) major shareholder Arch Venture Partners Xii, Llc purchased 170,000 shares of the business’s stock in a transaction dated Monday, October 19th. The shares were purchased at an average cost of $18.00 per share, with a total value of $3,060,000.00. Following the completion of the purchase, the insider directly owned 13,692,507 shares in the company, valued at approximately $246,465,126. This represents a 1.26% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
City Therapeutics Trading Down 4.2%
Shares of City Therapeutics stock traded down $0.94 during trading on Monday, hitting $21.46. 302,365 shares of the stock traded hands. City Therapeutics, Inc. has a twelve month low of $20.50 and a twelve month high of $23.88.
About City Therapeutics
See Also
- Five stocks we like better than City Therapeutics
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for City Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for City Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
